Gastric cancer patients positive for peritoneal cytology are at increased risk of tumor recurrence, but although a certain proportion of cytology-positive patients relapse rapidly with aggressive progression, others survive longer with conventional chemotherapies. This heterogeneity makes it difficult to stratify patients for more intensive therapy and poses a substantial challenge for the implementation of precision medicine. We developed a new approach to identify biologically malignant sub- -
| MATERIALS AND METHODS

| Cell line and recombinant adenovirus
The human non-small cell lung cancer cell line H1299 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured according to the manufacturer's specifications.
The cell line authentication was performed and reported by the Japanese Collection of Research Bioresources (JCRB) Cell Bank.
TelomeScan is a telomerase-specific replication-competent adenovirus variant, in which the hTERT gene promoter drives the expression of the E1A and E1B genes linked by an internal ribosome entry site, and in which the GFP gene is inserted into the deleted E3 region of the CMV promoter ( Figure 1A) . 13, 16, 19 TelomeScan was purified by ultracentrifugation using CsCl step gradients. Viral titers were determined by a plaque-forming assay using 293 cells, and the virus was stored at −80°C. This study was approved by the Recombinant DNA Experiment Safety Committee and carried out in accordance with the approved protocol (approval ID: 12015).
| Patients and clinical samples
A total of 68 patients with histologically proven gastric cancer were 
| Quantification of GFP-positive cells
The protocol of TelomeScan infection for clinical samples is shown in Figure 1B . When samples were bloody, red blood cells (RBC) were removed in advance using RBC lysis buffer (BioLegend, San Diego, CA, USA). Samples were centrifuged, and cell pellets resuspended in 1 mL RPMI-1640 medium. The total number of viable cells was counted, and then they were infected with TelomeScan at a multiplicity of infection (MOI) of 1 and incubated for 24 hours at 37°C with gentle rolling. GFP-expressing cells were subsequently counted under a fluorescence microscope in a black 96-well plate with a clear flat bottom.
When there were >1000 GFP-expressing cells, the total number of GFP-expressing cells was arbitrarily recorded as 1000. The fluorescence intensity of GFP was quantified using the SpectraMax i3 multimode microplate reader (Molecular Devices, Sunnyvale, CA, USA). The total number of GFP-expressing cells was calculated relative to the GFP intensity of TelomeScan-infected H1299 cells.
| Immunofluorescence staining
The cells were stained with anti-CD45 Life Technologies Corporation; Carlsbad, CA, USA) and Alexafluor568-goat anti-mouse IgG (Invitrogen) were used. The anti-CK antibody was labelled using the Zenon labelling kit (Invitrogen).
Immunofluorescence staining was evaluated under an inverted fluorescence microscope (IX71; Olympus, Tokyo Japan).
| DNA extraction from GFP-positive,
CD45-negative cells
The cells collected from peritoneal wash samples were infected with
TelomeScan at an MOI of 1 and incubated for 24 hours. Thereafter, cell pellets were labeled with anti-CD45 antibody conjugated with allophycocyanin (APC; BioLegend), and the GFP-positive CD45-negative cells were sorted using the FACS Aria (Becton Dickinson, San F I G U R E 1 A simple quantification of TelomeScan-positive cells using a multi-mode microplate reader. A, Schematic DNA structure of TelomeScan (OBP-401). TelomeScan is a telomerase-specific replication-competent adenovirus variant, in which the human telomerase reverse transcriptase promoter (hTERTp) element drives expression of the E1A and E1B genes linked by an internal ribosome entry site, and the green fluorescent protein (GFP) gene is inserted under the cytomegalovirus promoter (CMVp) into the deleted E3 region. B, Steps in the sample preparation for GFP-fluorescence detection. Samples were collected and initially incubated with red blood cell (RBC) lysis buffer for 3 min when bloody. After centrifugation and washing, cell pellets were resuspended in 1 mL RPMI-1640 medium, mixed with various concentrations of TelomeScan (finally fixed at 1 multiplicity of infection [MOI]), and incubated at 37°C with gentle rolling for another 24 h. Cells were subsequently resuspended in 1 mL RPMI-1640 medium following centrifugation and counted under a fluorescence microscope or enumerated with a multi-mode microplate reader. C, GFP-fluorescence intensity was measured using a fluorescence microplate reader with excitation/ emission at 473 nm/505 nm, optimized using TelomeScan-infected H1299 cells. to 10 (Table S1 ) and a preliminary cell line-based study ( Figure S1 )
confirmed that an MOI of 1 would be optimal for TelomeScan infection.
| Fluorescent intensity-based quantification of
TelomeScan-positive cells
The biggest advantage of the fluorescence-based detection of cancer cells by TelomeScan is the elimination of the need for subjective cytological assessments. To quantify cancer cells, samples were placed into 96-well plates and GFP-fluorescence intensity measured using a microplate reader with excitation/emission at 473 nm/ 505 nm (optimized using the human cancer cell line, H1299).
TelomeScan-infected GFP-positive cells and uninfected GFP-negative cells were mixed at various ratios ( Figure 1C ). The GFP intensity was measured over 21 points per well, and a calibration curve prepared ( Figure 1D ). According to the calibration curve, the number of TelomeScan negative (Figure 3) . Thus, we found a significant correlation (P = 0.0006). Based on the cytology results, the specificity, sensitivity, and accuracy of TelomeScan-guided cytology were 76.6%, 66.7%, and 73.5%, respectively.
| TelomeScan-guided peritoneal cytology stratifies gastric cancer prognosis
As expected, there were significant differences in overall survival stratified by conventional peritoneal wash cytology-positive or -negative status (P = 0.0011; Figure S4A ), and there were also significant differences in survival between TelomeScan-positive and -negative patients (P = 0.0126; Figure S4B ). Moreover, of the 21 patients who were positive on conventional cytology, the 14 patients who were also TelomeScan positive had significantly worse prognosis than the seven who were TelomeScan negative (P = 0.0062; Figure 4A ). The median survival time of TelomeScan-positive patients was 235 days, whereas that of TelomeScan-negative patients was 671 days.
No significant differences in age, sex, histological type, or liver metastasis were observed between the TelomeScan-positive and -negative groups, but the TelomeScan-positive group included nine patients who already had peritoneal metastasis, while in the TelomeScan-negative group there was only one patient with peritoneal metastasis (Table S2) . Interestingly, when patients with To make this technology broadly available to health-care providers,
we wished to develop a simple and objective detection method, According to the Japanese classification of gastric carcinoma. Given that we have confirmed the utility of this test in only a limited number of samples, it will be necessary to confirm this in a larger number of clinical samples. Nevertheless, the method is potentially very valuable because it does not require laborious techniques, such as the extraction of nucleic acids or staining with expensive antibodies, and does not rely on professional competence for diagnosis.
Although conventional cytology of peritoneal wash samples is the most reliable procedure at present, investigators have assessed a number of methods to improve the diagnostic accuracy of cytology using various detection assays. 10 Of these, PCR-based detection systems have been the most extensively investigated. 20, 21 The potential efficiency, high sensitivity, and objectiveness of this approach have been demonstrated by multiple investigators, but the lack of appropriate marker genes universally and specifically expressed in gastric cancer presents an important challenge for this approach. 22, 23 In contrast, the present virusbased system targets telomerase, which is known to be specifically and important to obtain samples of disseminated cells or metastatic tissues. 30 The increasing application of NGS makes it an important tool for both cancer diagnosis and therapeutic decision-making; 31 the NGS platform, however, requires certain amounts of target DNA. By excluding the hematopoietic CD45-positive cells, TelomeScan amplified the fluorescent signal and increased the tumor-specific signal-to-background ratio. 19 We detected a number of variants on 29 human gastric cancerrelevant genes, demonstrating that sufficient amounts of DNA can be recovered from disseminated tumor cells using the TelomeScan-guided capturing technology, although the correlation between these particular genetic changes and clinical outcome has yet to be assessed.
It is important to recognize some limitations of this technology. First, the TelomeScan procedure currently takes 24 hours for viral infection and protein expression, and it is therefore unsuitable for the rapid cytological diagnosis required, for example, in making decisions of surgical strategy in the operating room, where conventional cytology predominates over other diagnostics. This system would instead be useful in combination with conventional cytology when treating patients after surgery. After staging laparoscopy in particular, it is important to decide which type of anti-cancer drug is suitable for each patient from the point of conversion chemotherapy. 32 Second, the present sample size was relatively small, and patient background was not uniform. Although significant differences in prognosis were noted between TelomeScan-positive and -negative cases in the positive conventional cytology cohort, the most important clinical benefit would be the sub-stratification of those with negative conventional cytology, or to identify patients who might benefit from personalized therapy based on genetic profiling. Indeed, two cytology-negative patients with T1 tumors had TelomeScan-positive cells, but the origin of these cells has not been identified yet, even on multicolor immunohistochemistry. Moreover, in the cytology-negative cohort, the survival curves were not significantly different between the TelomeScan-positive and -negative population, presumably due to the small sample sizes (M. Watanabe, T. Fujiwara, et al., unpublished data).
Therefore, a large-scale multicenter prospective clinical study will soon be conducted to definitively establish the clinical significance of TelomeScan-guided fluorescent cytology for gastric cancer patients.
In conclusion, our unique nano-biologic, TelomeScan, successfully detected biologically active cancer cells in the peritoneal washes from gastric cancer patients, findings that were correlated with patient prognosis, demonstrating the potential utility of automated cytology diagnostics based on fluorescence intensity. We hope that this novel technology can add value to the information obtained from clinical peritoneal washes and can assist in improving the dismal prognosis of advanced gastric cancer in the near future.
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